Row

a. H5N1Giza challenge, AnhuiVACC

3.51 AU to center | GMT: 9 | 27 detectable titres

b. H5N1Giza challenge, AC-AnhuiVACC

2.25 AU to center | GMT: 27 | 69 detectable titres

c. H5N1Giza challenge, GizaVACC

2.73 AU to center | GMT: 16 | 48 detectable titres

Row

d. H5N6Sichuan challenge, AnhuiVACC

3.58 AU to center | GMT: 6 | 7 detectable titres

e. H5N6Sichuan challenge, AC-AnhuiVACC

1.70 AU to center | GMT: 10 | 38 detectable titres

f. H5N6Sichuan challenge, SichuanVACC

4.23 AU to center | GMT: 7 | 21 detectable titres

Row

Supplementary Data 8 | Mean antibody profiles upon vaccination with split-inactivated vaccines containing wild-type HA antigens or the antigenically central HA antigen.  
An interactive version of the antibody profiles displayed in Fig. 3. For each group, the position, breadth and height of a mean serum per group (n=6) are represented in the antigenic map from Supplementary Data 5b. (a-c) Immune responses upon vaccination with A(H5N6) split-inactivated vaccines in the H5N1Giza challenge study or (d-f) A(H5N1) split-inactivated vaccines in the H5N6Sichuan challenge study. HA antigens present in vaccine: (a, d) AnhuiVACC, (b, e) AC-AnhuiVACC, (c) GizaVACC and (f) SichuanVACC. Using the same representation as Supplementary Data 6. AU: antigenic unit; GMT: geometric mean titre.